Cepheid upgraded at Needham As previously reported, Needham upgraded Cepheid to Buy from Hold. The firm upgraded shares based on expectations for faster growth driven by recent international launches of HPV and Norovirus, virology expansion, and U.S. sales management changes that should driver faster growth. Price target is $50.
Cepheid upgraded to Buy from Hold at Craig-Hallum Craig-Hallum upgraded Cepheid to Buy and raised its price target to $75 from $52. The firm said Cepheid is rapidly expanding its clinical offering and customer reach and is emerging as the leading platform for molecular diagnostics.